VIVSHealthcare · BiotechnologyVIVS Stock Forecast: VivoSim Labs, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 1 Aug 2026 — in the lower half.
VIVS stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores VivoSim Labs, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (100): Smaller than most of the companies we track.
Value (4): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own VivoSim Labs, Inc. — and when they’d sell — is the membership.
VIVS stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on VIVS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
VIVS analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
VivoSim Labs, Inc. (VIVS) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.5×
- Price / sales
- 9.2×
- Price / book
- 0.2×
- EV / EBITDA
- 0.3×
Cheaper than 71% of US stocks
Cheaper than 15% of US stocks
Cheaper than 89% of US stocks
Cheaper than 60% of US stocks
- Revenue growth (YoY)
- −21.6%
- Earnings growth (YoY)
- −21.6%
- Gross margin
- 100.0%
- Operating margin
- −7967.5%
- Net margin
- 100.0%
Higher than 11% of US stocks
Higher than 19% of US stocks
Higher than 99% of US stocks
Higher than 2% of US stocks
Higher than 99% of US stocks
- Return on equity
- −294.8%
- Return on assets
- −65.2%
- Dividend yield
- —
Higher than 5% of US stocks
Higher than 6% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
VIVS vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VIVS appears on the weeks it earns a place.
Frequently asked questions about VIVS stock
How does Ticker Nerd's model rank VIVS?
As at 1 Aug 2026, VivoSim Labs, Inc. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (100 of 100).
What is the VIVS stock forecast for 2030?
No analyst covering VivoSim Labs, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VIVS are extrapolating price history, which says nothing about the business.
How has VIVS stock performed over the past year?
VivoSim Labs, Inc. returned -81.9% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does VivoSim Labs, Inc. do?
VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company specializing in the testing of drugs and drug candidates using advanced three-dimensional (3D) human tissue models of the liver and intestine.
About VivoSim Labs, Inc.
VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company specializing in the testing of drugs and drug candidates using advanced three-dimensional (3D) human tissue models of the liver and intestine. The company employs proprietary new approach methodologies (NAM) to provide detailed insights into liver and intestinal toxicology, aiding pharmaceutical and biotech partners in investigational toxicology, mechanism of drug action elucidation, and prediction of side effect profiles during drug development. VivoSim Labs builds functional 3D human tissues that closely mimic native tissue composition, architecture, and function, including disease states, utilizing high-throughput systems, bioprinting, and flow/stretch-capable technologies. Formerly known as Organovo Holdings, Inc., the company was renamed in April 2025 and has its headquarters in San Diego, California. VivoSim Labs plays a significant role in advancing drug safety and efficacy testing through sophisticated tissue engineering and predictive toxicology platforms, contributing to improved preclinical evaluation in the healthcare biotechnology sector.
9 employees · United States · https://vivosim.ai